Overview

Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment

Status:
RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral glucose tolerance test.
Phase:
PHASE4
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Treatments:
Cabergoline
Dopamine Agonists